Skip to main content

Table 3 Select phase III trials of first, second, and third generation trials

From: Progress in adjuvant chemotherapy for breast cancer: an overview

Generation Comparison (Reference) Nodal status Number of patients Median follow-up (years) Hazard ratio for disease-free survival Hazard ratio for overall survival
First CMF vs no chemo [22, 71] Positive 386 28.5 0.71 (P = 0.005) 0.79 (P = 0.04)
  CMF + Tam vs Tam (B20) [26] Negative 2306 5 0.65 (P = 0.001) 0.64 (P = 0.03)
  AC vs CMF (B15) [72, 73] Positive 2194 3 P = 0.5* P = 0.8*
  AC vs CMF (B23) [74] Negative 2008 5 P = 0.9* P = 0.4*
  FEC50 + Tam vs Tam [76] Positive 457 9.4 0.46 (P = 0.0008) 0.65 (P = 0.07)
Second FEC100 vs FEC50 [78] Positive 546 5.6 0.63 (P = 0.02) 0.45 (P = 0.005)
  ACx4-Tx4 vs ACx4 (C9344) [82] Positive 3121 5.8 0.83 (P = 0.002) 0.82 (P = 0.006)
  ACx4-Tx4 vs ACx4 (B28) [83] Positive 3060 5.4 0.83 (P = 0.006) 0.93 (P = 0.46)
  DCx4 vs ACx4 [85] 0–3 Positive 1016 7 0.74 (P = 0.033) 0.69 (P = 0.032)
  Ex4-CMFx4 vs CMFx6/CMFx8 [84] Positive Negative 2391 4 0.69 (P <0.001) 0.67 (P <0.001)
Third DAC vs FAC [89, 112] Positive 1491 10.3 0.80 (P = 0.004) 0.74 (P = 0.002)
  DAC vs FAC [91] Negative 1060 6.4 0.68 (P = 0.01) 0.76 (P = 0.29)
  FEC-D vs FEC [92, 93] Positive 1099 7.8 0.85 (P = 0.036) 0.75 (P = 0.007)
  FEC-weekly T vs FEC [95] Positive 1246 5.5 0.77 (P = 0.022) 0.78 (P = 0.11)
  FAC-weekly T vs FAC [113] Negative 1925 5.3 0.73 (P = 0.04) 0.79 (P = 0.31)
  Q3 vs q2wk ACT [97, 98] Positive 2005 5.8 0.80 (P = 0.01) 0.85 (P = 0.04)
  AC-T vs AC-weekly T [100, 101] Positive 4954 12.1 0.84 (P = 0.011) 0.87 (P = 0.09)
AC-T vs AC-D 0.79 (P = 0.001 0.86 (P = 0.054)
  AC-D vs DAC [103] Positive 5351 6.1 0.83 (P = 0.01) 0.86 (P = 0.09)
AC-D vs AD 0.80 (P = 0.001) 0.83 (P = 0.03)
  1. CMF, Cyclophosphamide, methotrexate, 5-flourouracil; AC, Doxorubicin, cyclophosphamide; FEC50, 5-flourouracil, epirubicin (50 mg/m2), cyclophosphamide; FEC100, 5-flourouracil, epirubicin (100 mg/m2), cyclophosphamide; DC, Docetaxel, cyclophosphamide; CAF, Cyclophosphamide, doxorubicin, 5-flourouracil; FAC, 5-flouroracil, doxorubicin, cyclophosphamide; DAC, Docetaxel, doxorubicin, cyclophosphamide; T, Paclitaxel; D, Docetaxel; E, Epirubicin
  2. *Hazard ratios were not reported in the manuscript; however P values did not reveal any statistical significance between study arms